Nectar Lifesciences Limited (NECLIFE)

Loading page…

Nectar Lifesciences Limited (NECLIFE) · mywealthgrid

About

Nectar Lifesciences: small-cap pharmaceutical company, ₹218.2 Cr market cap. Recent quarters show near-zero revenue and substantial operating losses — core business contracted sharply. In severe operational distress with unclear recovery path.

Face value: ₹1

Market cap

₹199 Cr

P/E

—

P/B

0.3×

Dividend yield

ROE

-38.1%

ROCE

-6.4%

Debt / equity

OPM

—

EPS (TTM)

₹-12.6

Book value

₹30.0

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

Losses of ₹176.01 Cr (Sep 2025), ₹67.92 Cr (Mar 2026); revenue collapsed to ₹0–₹0.01 Cr in most quarters — verify core business viability, asset impairment, going-concern status
ROE at -38.08% signals shareholder value destruction — verify balance-sheet health, inventory write-downs, whether losses are operational or from asset impairments
Revenue volatility: ₹5 Cr (Sep 2025) fell to ₹0 (Mar–Jun 2026) — verify cause (product discontinuation, supply failure, demand collapse, regulatory issue)
Single profitable quarter (Dec 2025, ₹14.27 Cr) amid persistent losses — verify if core operations or one-off event (asset sale, restructuring gain)

Generated analysis · source review pending

Growth drivers

Sep 2025 revenue of ₹5 Cr was highest recent; verify recoverability and growth path of this stream
Zero debt (D/E 0) enables turnaround if operations stabilize; verify management's strategic plan and capital allocation
No dividend since 2020 means cash retention; verify cash position and allocation to product development and R&D
Dec 2025 profit of ₹14.27 Cr offers margin recovery template if repeatable; verify root cause and sustainability

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹10.2-4.5%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of -16.3% (3-yr avg)
−Weak interest coverage of -1.4×

Research score

Structured signal from quality, growth, valuation and momentum.

42/100

Business quality: 25
Growth: 0
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,793	1,744	2,093	3,113	2,367	1,544	1,669	1,525	1,686	1,673	0
COGS	-25	—	—	—	1,859	1,157	1,223	1,159	1,202	1,368	0
Gross profit	—	—	—	—	508	387	446	365	483	305	—
	—	—	—	—	288	277	287	311	330	332	61
	—	—	—	—	220	110	159	54	153	-26	-61
OPM %	—	—	—	—	9.3%	7.1%	9.5%	3.5%	9.1%	-1.6%	—
Depreciation	57	62	64	63	61	60	57	59	61	62	0
Interest	123	117	115	148	126	112	79	79	87	75	36
	6	23	6	6	4	-23	11	42	13	2	-226
Profit before tax	64	67	63	59	37	-85	34	-42	18	-162	-323
Tax	10	12	10	11	6	-12	9	-18	13	-48	-31
Tax %	15%	17.9%	16.6%	19.1%	15.2%	-13.6%	26.5%	-43%	72.6%	-29.6%	-9.4%
	54	55	52	48	32	-73	25	-24	5	-114	-293
PAT margin %	3%	3.2%	2.5%	1.5%	1.3%	-4.7%	1.5%	-1.6%	0.3%	-6.8%	—
EPS (₹)	2.4	2.5	2.3	2.1	1.4	-3.3	1.1	-1.1	0.2	-5.1	-13.4
EPS adjusted (₹)	2.4	2.5	2.3	2.1	1.4	-3.3	1.1	-1.1	0.2	-5.1	-15.1
	4.1%	2%	2.1%	2.4%	3.5%	—	0%	—	0%	—	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	22	22	22	22	22	22	22	22	22	22	19
Reserves	880	984	1,036	1,083	1,114	1,040	1,065	1,042	1,047	934	563
	861	794	854	802	741	840	794	754	636	582	0
	667	780	811	798	756	486	509	371	486	509	39
Total equity & liabilities	2,430	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	622
	889	881	852	825	785	772	723	662	643	633	105
CWIP	91	102	100	100	115	99	85	78	66	57	0
Investments	1	1	1	1	0	1	1	1	1	1	13
	1,449	1,597	1,771	1,780	1,733	1,517	1,582	1,449	1,482	1,357	504
Total assets	2,430	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	622

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	21.5%	25.1%	26.7%	24%	28.7%	18.2%	—
EBITDA margin %	—	9.3%	7.1%	9.5%	3.5%	9.1%	-1.6%	—
EBIT margin %	—	6.7%	3.2%	6.1%	-0.3%	5.5%	-5.3%	—
PAT margin %	1.5%	1.3%	-4.7%	1.5%	-1.6%	0.3%	-6.8%	—
Working capital
Receivable days	66	62	89	98	67	82	75	—
Inventory days	—	—	265	260	212	215	184	—
Payable days	—	—	108	112	100	127	117	—
NWC days	—	—	245	246	178	170	143	—
Leverage
Current ratio	1.28	1.29	1.25	1.56	1.38	1.32	1.21	9.71
Debt to EBITDA	—	3.37	7.63	5.01	13.97	4.15	—	—
Debt to equity	0.73	0.65	0.79	0.73	0.71	0.59	0.61	0
Interest coverage	-0.4	1.3	0.5	1.4	0.5	1.2	-1.2	-1.4
Asset turnover	1.15	0.9	0.65	0.7	0.7	0.77	0.82	0
Return ratios
Return on assets %	1.8%	1.2%	-3.1%	1%	-1.1%	0.2%	-5.6%	-47.1%
Return on capital employed %	-4.1%	11.7%	4.1%	8.7%	2.8%	8.4%	-7.8%	-6.4%
Return on equity %	4.3%	2.8%	-6.9%	2.3%	-2.3%	0.5%	-11.9%	-50.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	55.8%	55.8%	55.8%	55.8%	55.8%	44.53%	44.53%	44.53%	44.91%	44.91%	51.84%	51.84%
	16.01%	16.11%	16.97%	16.61%	3.24%	0.73%	1.65%	0.81%	0.62%	0.52%	0.6%	0.5%
	0%	0%	0%	0%	0%	0%	0.16%	0.19%	0.09%	0%	0%	0.01%
	0%	0%	0%	0%	0%	0%	0%	0%	0.02%	5.84%	4.03%	3.75%
	28.19%	28.09%	27.23%	27.59%	40.96%	54.74%	53.66%	54.47%	54.36%	48.73%	43.53%	43.9%
No. of shareholders	—	—	—	—	—	—	—	—	76,470	78,124	74,834	73,834

Promoter holding down 3.96 percentage points since Sep 2023.

2 disclosures

Person	Deal	Shares	Value	Holding	Filed
SBICAP Trustee Company LimitedOther	Pledge Revoke	9,94,68,000	₹92.37 cr	—	4 Nov 20257(2)
Sanjiv GoyalPromoters	Pledge Revoke	4,36,22,400	₹68.75 cr	19.45% → 19.45%	30 Oct 2025

78 deals · 20 Dec 2023 – 4 Dec 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
4 Dec 2025	JAIDEEP SAMPAT	Bulk	NSE	Sell	16,95,746	₹20.54	₹3.48 Cr
4 Dec 2025	RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED	Bulk	NSE	Buy	15,00,000	₹20.87	₹3.13 Cr
4 Dec 2025	MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED	Bulk	NSE	Buy	15,00,000	₹20.93	₹3.14 Cr
4 Dec 2025	IRAGE BROKING SERVICES LLP	Bulk	NSE	Sell	14,79,033	₹20.47	₹3.03 Cr
4 Dec 2025	ANKITA VISHAL SHAH	Bulk	NSE	Sell	13,49,525	₹20.65	₹2.79 Cr
4 Dec 2025	ANKITA VISHAL SHAH	Bulk	NSE	Buy	13,49,525	₹21.01	₹2.84 Cr
4 Dec 2025	QE SECURITIES LLP	Bulk	NSE	Sell	12,66,933	₹20.36	₹2.58 Cr
4 Dec 2025	QE SECURITIES LLP	Bulk	NSE	Buy	11,80,239	₹20.60	₹2.43 Cr
4 Dec 2025	IRAGE BROKING SERVICES LLP	Bulk	NSE	Buy	8,00,112	₹20.48	₹1.64 Cr
11 Jul 2025	L7 HITECH PRIVATE LIMITED	Bulk	NSE	Sell	18,05,000	₹19.97	₹3.60 Cr

1–10 of 78

1 / 8

Mr. SANJIV GOYALExecutive Director-Chairperson related to Promoter-MD
Mr. RUPINDER TEWARINon-Executive - Independent Director
Mr. KULDIP KUMAR BHASINNon-Executive - Independent Director
Ms. INDU PAL KAURNon-Executive - Independent Director
Mr. SUSHIL KAPOORExecutive Director
Mr. Sanjaymohan Singh RawatCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	2,558	0	0.01%	0.001%	+4

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

14

Final dividend11 Sept 2020 · ex-date₹0.05
Final dividend19 Sept 2019 · ex-date₹0.05
Final dividend19 Sept 2018 · ex-date₹0.05
Final dividend20 Sept 2017 · ex-date₹0.05
Final dividend22 Sept 2016 · ex-date₹0.1
Final dividend22 Sept 2015 · ex-date₹0.1
Final dividend21 Aug 2014 · ex-date₹0.1
Final dividend19 Sept 2013 · ex-date₹0.1
Final dividend20 Sept 2012 · ex-date₹0.1
Final dividend21 Sept 2011 · ex-date₹0.1
Interim dividend21 Jan 2010 · ex-date₹0.25
Final dividend3 Sept 2009 · ex-date₹0.1
Final dividend18 Sept 2008 · ex-date₹4
Final dividend18 Sept 2007 · ex-date₹2

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

17 announcementsExport CSV

19 Sept 2026, 11:54 amCompany Update

Revised Proceedings Of 31St Annual General Meeting (''AGM'')

General PDF

18 Sept 2026, 5:24 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

18 Sept 2026, 12:25 pmAGM/EGM

Proceedings Of 31St Annual General Meeting ('AGM')

AGM PDF

22 Aug 2026, 2:32 pmCompany Update

Letter Sent To Members

General PDF

21 Aug 2026, 12:08 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

20 Aug 2026, 11:41 amOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

20 Aug 2026, 11:00 amAGM/EGM

Notice Of 31St Annual General Meeting ('AGM') For The Financial Year 2025-26

AGM PDF

20 Aug 2026, 10:45 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
19 Sept 2026, 11:54 am	Company Update General	Revised Proceedings Of 31St Annual General Meeting (''AGM'')	PDF
18 Sept 2026, 5:24 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	21.5%	25.1%	26.7%	24%	28.7%	18.2%	—
EBITDA margin %	—	9.3%	7.1%	9.5%	3.5%	9.1%	-1.6%	—
EBIT margin %	—	6.7%	3.2%	6.1%	-0.3%	5.5%	-5.3%	—
PAT margin %	1.5%	1.3%	-4.7%	1.5%	-1.6%	0.3%	-6.8%	—
Working capital
Receivable days	66	62	89	98	67	82	75	—
Inventory days	—	—	265	260	212	215	184	—
Payable days	—	—	108	112	100	127	117	—
NWC days	—	—	245	246	178	170	143	—
Leverage
Current ratio	1.28	1.29	1.25	1.56	1.38	1.32	1.21	9.71
Debt to EBITDA	—	3.37	7.63	5.01	13.97	4.15	—	—
Debt to equity	0.73	0.65	0.79	0.73	0.71	0.59	0.61	0
Interest coverage	-0.4	1.3	0.5	1.4	0.5	1.2	-1.2	-1.4
Asset turnover	1.15	0.9	0.65	0.7	0.7	0.77	0.82	0
Return ratios
Return on assets %	1.8%	1.2%	-3.1%	1%	-1.1%	0.2%	-5.6%	-47.1%
Return on capital employed %	-4.1%	11.7%	4.1%	8.7%	2.8%	8.4%	-7.8%	-6.4%
Return on equity %	4.3%	2.8%	-6.9%	2.3%	-2.3%	0.5%	-11.9%	-50.3%

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	169	199	65	239	285	21	95	134	225	169	-349
	-77	-18	-29	-26	-33	-29	17	52	-17	-42	1,208
	-89	-204	-40	-201	-252	11	-119	-186	-205	-128	-767
Net cash flow	3	-23	-4	12	-0	4	-8	-0	2	-1	93
Free cash flow	86	145	32	201	230	-10	70	104	195	126	-361
CFO / Operating profit %	—	—	—	—	129.5%	19.4%	59.9%	247.7%	146.8%	—	—

Nectar Lifesciences Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Events

Dividends14

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Dividends14

Board meetings1

Announcements

Annual reports

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

14

1

14

1